should mrd guide myeloma treatment? a debate. | rahul banerjee, md and sridevi rajeeve, md |ims 2024
Published 1 month ago • 276 plays • Length 8:53Download video MP4
Download video MP3
Similar videos
-
10:11
timing for myeloma car-t therapy: a debate | rahul banerjee, md and sridevi rajeeve, md | ims 2024
-
3:34
predictors of delayed responses to teclistamab in myeloma | rahul banerjee, md | ims 2024
-
3:38
healthtree study: dexamethasone's impact on eye health in myeloma | rahul banerjee, md | ims 2024
-
3:37
is remote monitoring for crs in the future? | sridevi rajeeve, md | ash 2021
-
1:11:05
the utility of mrd testing for myeloma patient treatment and outcomes
-
6:23
how long will i live with multiple myeloma, and is there a cure? #myeloma
-
5:24
dr. noopur raje discusses kidney disease in multiple myeloma
-
42:05
how to manage bone disease in multiple myeloma by dr. andrew yee
-
27:13
changing landscape of multiple myeloma care: expert discussion
-
2:53
how will i know if my myeloma treatment is working?
-
3:01
the benefit of using mrd to guide treatment decisions in multiple myeloma
-
32:18
myeloma treatment decisions: what’s right for you?
-
1:54
why consider maintenance therapy if i am in a complete response?
-
1:22
future treatment options for multiple myeloma
-
1:02
should frontline myeloma treatment include a 3- or 4-drug regimen?
-
50:52
healthtree podcast for myeloma: shaji kumar, md, mayo clinic on etbs in myeloma
-
1:30
mrd: an important topic in myeloma therapy
-
2:56
how is myeloma treatment response measured?
-
3:43
will it be possible to prevent multiple myeloma?
-
5:15
is mrd testing routinely recommended for myeloma patients?
-
11:32
are we ready to use mrd for treatment decisions in patients with mm?
-
2:03
what long-term strategies should myeloma patients understand? #myeloma